Exact Sciences Corp
NASDAQ:EXAS

Watchlist Manager
Exact Sciences Corp Logo
Exact Sciences Corp
NASDAQ:EXAS
Watchlist
Price: 52.91 USD -0.3% Market Closed
Market Cap: 9.8B USD
Have any thoughts about
Exact Sciences Corp?
Write Note

Wall Street
Price Targets

EXAS Price Targets Summary
Exact Sciences Corp

Wall Street analysts forecast EXAS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EXAS is 72.99 USD with a low forecast of 60.6 USD and a high forecast of 93.67 USD.

Lowest
Price Target
60.6 USD
15% Upside
Average
Price Target
72.99 USD
38% Upside
Highest
Price Target
93.67 USD
77% Upside

EXAS Last Price Targets
Exact Sciences Corp

The latest public price target was made on Nov 6, 2024 by Catherine Schulte from Robert W. Baird , who expects EXAS stock to rise by 27% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Catherine Schulte
Robert W. Baird
67 USD
Upside 27%
2 weeks ago
Nov 6, 2024
Exact Sciences (EXAS) PT Lowered to $67 at Baird
StreetInsider
Mark Massaro
BTIG
65 USD
Upside 23%
2 weeks ago
Nov 6, 2024
Exact Sciences (EXAS) PT Lowered to $65 at BTIG
StreetInsider
Kyle Mikson
Canaccord Genuity
95 USD
Upside 80%
3 weeks ago
Oct 29, 2024
Exact Sciences (EXAS) PT Raised to $95 at Canaccord Genuity
StreetInsider
Vijay Kumar
Evercore ISI
80 USD
Upside 51%
1 month ago
Oct 1, 2024
Exact Sciences price target raised to $80 from $72 at Evercore ISI
TheFly
Mark Massaro
BTIG
82 USD
Upside 55%
2 months ago
Sep 16, 2024
Exact Sciences price target raised to $82 from $70 at BTIG
TheFly
Patrick Donnelly
Citigroup
80 USD
Upside 51%
2 months ago
Sep 16, 2024
Citi Reiterates Buy Rating on Exact Sciences (EXAS)
StreetInsider
Kyle Mikson
Canaccord Genuity
75 USD
Upside 42%
2 months ago
Sep 13, 2024
Canaccord Genuity Reiterates Buy Rating on Exact Sciences (EXAS)
StreetInsider
David Westenberg
Piper Sandler
85 USD
Upside 61%
2 months ago
Sep 12, 2024
Exact Sciences (EXAS) PT Raised to $85 at Piper Sandler
StreetInsider
David Westenberg
Piper Sandler
80 USD
Upside 51%
4 months ago
Jul 19, 2024
Piper Sandler Reiterates Overweight Rating on Exact Sciences (EXAS)
StreetInsider
Mark Massaro
BTIG
70 USD
Upside 32%
4 months ago
Jun 26, 2024
Exact Sciences price target lowered to $70 from $80 at BTIG
TheFly
Sung Ji Nam
Scotiabank
70 USD
Upside 32%
4 months ago
Jun 26, 2024
Exact Sciences initiated with an Outperform at Scotiabank
TheFly
Tycho Peterson
Jefferies
75 USD
Upside 42%
5 months ago
Jun 3, 2024
Exact Sciences assumed with a Buy at Jefferies
TheFly
Kyle Mikson
Canaccord Genuity
85 USD
Upside 61%
6 months ago
May 9, 2024
Exact Sciences price target lowered to $85 from $90 at Canaccord
TheFly
Patrick Donnelly
Citigroup
130 USD
Upside 146%
1 year ago
Jun 22, 2023
Exact Sciences Set To Dominate Emerging Precision Oncology Market: Analyst Applauds $18B Potential Market
Benzinga
Show More Price Targets
Show Less Price Targets
Catherine Schulte
Robert W. Baird
Price Target 67 USD
Upside/Downside 27%
View Source
Mark Massaro
BTIG
Price Target 65 USD
Upside/Downside 23%
View Source
Kyle Mikson
Canaccord Genuity
Price Target 95 USD
Upside/Downside 80%
View Source
Vijay Kumar
Evercore ISI
Price Target 80 USD
Upside/Downside 51%
View Source
Mark Massaro
BTIG
Price Target 82 USD
Upside/Downside 55%
View Source
Patrick Donnelly
Citigroup
Price Target 80 USD
Upside/Downside 51%
View Source
Kyle Mikson
Canaccord Genuity
Price Target 75 USD
Upside/Downside 42%
View Source
David Westenberg
Piper Sandler
Price Target 85 USD
Upside/Downside 61%
View Source
David Westenberg
Piper Sandler
Price Target 80 USD
Upside/Downside 51%
View Source
Mark Massaro
BTIG
Price Target 70 USD
Upside/Downside 32%
View Source
Sung Ji Nam
Scotiabank
Price Target 70 USD
Upside/Downside 32%
View Source
Tycho Peterson
Jefferies
Price Target 75 USD
Upside/Downside 42%
View Source
Kyle Mikson
Canaccord Genuity
Price Target 85 USD
Upside/Downside 61%
View Source
Patrick Donnelly
Citigroup
Price Target 130 USD
Upside/Downside 146%
View Source
Show More Price Targets
Show Less Price Targets
Exact Sciences Corp Competitors:
Price Targets
STTK
Shattuck Labs Inc
103% Upside
RCUS
Arcus Biosciences Inc
136% Upside
OCX
OncoCyte Corp
55% Upside
OCC
Orthocell Ltd
9% Downside
GNS
Genus PLC
51% Upside
PTGX
Protagonist Therapeutics Inc
19% Upside
BONEX
Bonesupport Holding AB
4% Upside
EXAI
Exscientia PLC
13% Upside

Revenue
Forecast

Revenue Estimate
Exact Sciences Corp

For the last 8 years the compound annual growth rate for Exact Sciences Corp's revenue is 68%. The projected CAGR for the next 3 years is 12%.

68%
Past Growth
12%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Exact Sciences Corp

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Net Income
Forecast

Net Income Estimate
Exact Sciences Corp

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-31%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is EXAS's stock price target?
Price Target
72.99 USD

According to Wall Street analysts, the average 1-year price target for EXAS is 72.99 USD with a low forecast of 60.6 USD and a high forecast of 93.67 USD.

What is Exact Sciences Corp's Revenue forecast?
Projected CAGR
12%

For the last 8 years the compound annual growth rate for Exact Sciences Corp's revenue is 68%. The projected CAGR for the next 3 years is 12%.

Back to Top